IP Library Patent Application 18941301
Patent Application
App. No. 18/941,301

THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/941,301
Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Claims (18)

1 . A pharmaceutical composition comprising a crystalline form of 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid:

and

a pharmaceutically acceptable excipient.

2 . The pharmaceutical composition of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern comprising three or more characteristic peaks expressed in degrees two-theta to within 0.2° selected from 9.0°, 15.7°, 17.3°, 17.6°, 18.1°, 21.3°, 22.4°, 23.5°, 24.9°, 27.2°, 27.4°, 28.1°, 29.1°, 31.2°, and 35.7°.

3 . The pharmaceutical composition of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees two-theta to within 0.2° at 9.0°, 17.3°, and 18.1°.

4 . The pharmaceutical composition of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern substantially identical to FIG. 3 .

5 . The pharmaceutical composition of claim 1 , wherein the crystalline form has a melting point of about 155° C.

6 . The pharmaceutical composition of claim 2 , wherein the crystalline form has a melting point of about 155° C.

7 . The pharmaceutical composition of claim 1 , further comprising an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.

8 . The pharmaceutical composition of claim 7 , wherein the additional medicament is an antibacterial agent, and wherein the antibacterial agent is a β-lactam antibacterial agent selected from the group consisting of Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Aztreonam, Tigemonam, BAL30072, SYN 2416, and Carumonam.

9 . The pharmaceutical composition of claim 8 , wherein the additional medicament is Meropenem.

10 . A method of treating or preventing a bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .

11 . The method of claim 10 , further comprising administering an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.

12 . The method of claim 11 , wherein the additional medicament is administered in a separate composition or in the composition of claim 1 .

13 . The method of claim 11 , wherein the additional medicament is an antibacterial agent, and wherein the antibacterial agent is a β-lactam antibacterial agent selected from the group consisting of Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Aztreonam, Tigemonam, BAL30072, SYN 2416, and Carumonam.

14 . The method of claim 13 , wherein the additional medicament is Meropenem.

15 . The method of claim 10 , wherein the subject is a mammal.

16 . The method of claim 15 , wherein the mammal is a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: HIRST, GAVIN; REDDY, RAJA; HECKER, SCOTT; TOTROV, MAXIM; GRIFFITH, DAVID C.; RODNY, OLGA; DUDLEY, MICHAEL N.; BOYER, SERGE
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 071947/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2025
From: REMPEX PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 071947/0302 →
CHANGE OF NAME Recorded Aug 6, 2025
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 071947/0430 →